Bradley Foster & Sargent Inc. CT lowered its position in Zoetis Inc (NYSE:ZTS) by 0.8% during the 4th quarter, HoldingsChannel.com reports. The firm owned 291,436 shares of the company’s stock after selling 2,255 shares during the quarter. Bradley Foster & Sargent Inc. CT’s holdings in Zoetis were worth $20,995,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also recently made changes to their positions in ZTS. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in shares of Zoetis in the fourth quarter valued at approximately $108,000. Steward Partners Investment Advisory LLC acquired a new stake in shares of Zoetis in the third quarter valued at approximately $114,000. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its stake in shares of Zoetis by 251.9% in the third quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,900 shares of the company’s stock valued at $121,000 after purchasing an additional 1,360 shares during the period. Shine Investment Advisory Services Inc. increased its stake in shares of Zoetis by 86.5% in the third quarter. Shine Investment Advisory Services Inc. now owns 2,242 shares of the company’s stock valued at $143,000 after purchasing an additional 1,040 shares during the period. Finally, McKinley Carter Wealth Services Inc. acquired a new stake in shares of Zoetis in the third quarter valued at approximately $201,000. Institutional investors own 93.73% of the company’s stock.
Zoetis Inc (ZTS) opened at $73.86 on Thursday. Zoetis Inc has a 12 month low of $52.00 and a 12 month high of $80.13. The company has a current ratio of 2.80, a quick ratio of 1.95 and a debt-to-equity ratio of 2.45. The company has a market cap of $35,990.00, a P/E ratio of 38.87, a P/E/G ratio of 1.63 and a beta of 1.07.
ZTS has been the topic of several analyst reports. BMO Capital Markets restated a “hold” rating and issued a $65.00 price target on shares of Zoetis in a research note on Thursday, November 2nd. Cowen set a $80.00 price target on shares of Zoetis and gave the company a “buy” rating in a research note on Friday, November 17th. Morgan Stanley upgraded shares of Zoetis from an “equal weight” rating to an “overweight” rating and set a $80.00 price target on the stock in a research note on Wednesday, November 29th. UBS Group restated a “neutral” rating on shares of Zoetis in a research note on Friday, November 24th. Finally, Citigroup upgraded shares of Zoetis from a “neutral” rating to a “buy” rating and set a $85.00 price target on the stock in a research note on Thursday, January 4th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and fourteen have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $73.72.
TRADEMARK VIOLATION WARNING: “Bradley Foster & Sargent Inc. CT Has $21 Million Holdings in Zoetis Inc (ZTS)” was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://sportsperspectives.com/2018/02/08/bradley-foster-sargent-inc-ct-has-21-million-holdings-in-zoetis-inc-zts.html.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.